Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Active Biotech AB ( (SE:ACTI) ) just unveiled an update.
Active Biotech AB has initiated a rights issue to raise approximately SEK 70.3 million, with an additional SEK 10.0 million possible through an over-allotment option. The funds will support ongoing studies and business development activities, potentially impacting the company’s operations and market positioning by advancing their clinical projects.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company is engaged in clinical development projects, including tasquinimod for hematological malignancies and laquinimod for inflammatory eye disorders.
Average Trading Volume: 6,555,902
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK171.3M
For a thorough assessment of ACTI stock, go to TipRanks’ Stock Analysis page.